News By Tag
News By Location
SciTech to Present at 2020 MedInvest Virtual Infectious Diseases and Immunology Conference
By: SciTech Deevelopment LLC
Earle Holsapple (SciTech President) and Dr. Brian Leyland-Jones (SciTech Chief Medical Officer) will be presenting the company's lead oncology drug ST-001 nanoFenretinide which is being leveraged as a COVID-19 therapeutic. The company's virtual presentation is scheduled for
Date: Monday, June 15, 2020
Time: 1:30 PM (ET)
Qualified investors can register to attend the virtual conference for free. Visit www.medinvestconferences.com for additional information or call Earle Holsapple at (313) 938-5517 to schedule 1-on-1 virtual meetings which will continue to be held June 15-17, 2020.
ST-001 nanoFenretinide may offer additional support in the battle against the COVID-19 pandemic. The drug recently demonstrated antiviral activity against SARS-CoV-2; and, published data supports the use of the active agent fenretinide as an anti-inflammatory agent. SciTech is seeking immediate funding to enter a COVID-19 Phase 1 clinical trial that leverages the company's existing FDA approved IND for an oncology indication.
About SciTech Development
SciTech Development, LLC, is a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics. SciTech's patented and differentiated drug delivery system, SDV, is a proprietary intravenous, phospholipid-
Dr. Louis M. Scarmoutzos